• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高密度脂蛋白(HDL)患者心脏风险(QRISK2)计算器的局限性

Limitations of a Cardiac Risk (QRISK2) Calculator in Patients with High Density Lipoprotein (HDL).

作者信息

Minhas Jatinder S, Patel Prashanth, Gupta Pankaj K

机构信息

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.

NIHR Leicester Cardiovascular Biomedical Research Unit, Leicester, UK.

出版信息

High Blood Press Cardiovasc Prev. 2016 Mar;23(1):47-50. doi: 10.1007/s40292-016-0131-x. Epub 2016 Feb 23.

DOI:10.1007/s40292-016-0131-x
PMID:26905417
Abstract

INTRODUCTION

There is existing debate as to the relationship between blood concentration of HDL (high density lipoprotein) and cardiovascular outcomes. Patients with hyperalphalipoproteinaemia (HALP) have high HDL levels and this can be attributed to a variety of factors.

AIM AND METHODS

This study aims for the first time to examine the HALP cohort and understand demographics, relationship with cardiovascular disease (CVD) risk and scoring with a cardiac risk calculator (QRISK 2 calculator).

RESULTS

The study found 42 patients had a statistically significant difference (p = 0.001) between CVD risk estimated using actual measured HDL (Score 1) versus CVD risk calculated using standard population mean HDL values (Score 2). Furthermore, in the CVD event group (n = 6) a significant difference was also seen between Score 1 and Score 2 (p = 0.027).

CONCLUSION

The study highlights issues with underestimation of CVD risk in this population and strongly advocates use of standard population mean values in assessment of CVD risk.

摘要

引言

关于高密度脂蛋白(HDL)血液浓度与心血管疾病转归之间的关系,目前存在争议。高α脂蛋白血症(HALP)患者的HDL水平较高,这可归因于多种因素。

目的与方法

本研究首次旨在对HALP队列进行研究,并了解其人口统计学特征、与心血管疾病(CVD)风险的关系以及使用心脏风险计算器(QRISK 2计算器)进行评分的情况。

结果

研究发现,42例患者使用实际测量的HDL估算的CVD风险(评分1)与使用标准人群平均HDL值计算的CVD风险(评分2)之间存在统计学显著差异(p = 0.001)。此外,在CVD事件组(n = 6)中,评分1和评分2之间也存在显著差异(p = 0.027)。

结论

该研究突出了该人群中CVD风险被低估的问题,并强烈主张在评估CVD风险时使用标准人群平均值。

相似文献

1
Limitations of a Cardiac Risk (QRISK2) Calculator in Patients with High Density Lipoprotein (HDL).高密度脂蛋白(HDL)患者心脏风险(QRISK2)计算器的局限性
High Blood Press Cardiovasc Prev. 2016 Mar;23(1):47-50. doi: 10.1007/s40292-016-0131-x. Epub 2016 Feb 23.
2
Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome.人类高α脂蛋白血症伴发的矛盾性冠心病与高密度脂蛋白磷神经鞘脂组之间存在显著差异。
J Clin Lipidol. 2017 Sep-Oct;11(5):1192-1200.e3. doi: 10.1016/j.jacl.2017.06.018. Epub 2017 Jul 8.
3
Usefulness of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as Predictors of Cardiovascular Disease in Chinese.低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇作为中国人群心血管疾病预测指标的效用
Am J Cardiol. 2015 Oct 1;116(7):1063-70. doi: 10.1016/j.amjcard.2015.06.040. Epub 2015 Jul 16.
4
The relationship between cardiovascular disease risk prediction scores and vascular function and morphology in rheumatoid arthritis.类风湿关节炎中心血管疾病风险预测评分与血管功能及形态的关系
Clin Exp Rheumatol. 2014 Nov-Dec;32(6):914-21. Epub 2014 Aug 15.
5
High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.高密度脂蛋白亚类检测可改善心脏导管插入术队列中的死亡风险预测、区分能力及重新分类。
Atherosclerosis. 2016 Mar;246:229-35. doi: 10.1016/j.atherosclerosis.2016.01.012. Epub 2016 Jan 11.
6
Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria.识别心血管疾病风险和结局:使用血浆甘油三酯/高密度脂蛋白胆固醇浓度比值与代谢综合征标准。
J Intern Med. 2013 Jun;273(6):595-601. doi: 10.1111/joim.12036. Epub 2013 Feb 18.
7
Improved plasma cholesterol efflux capacity from human macrophages in patients with hyperalphalipoproteinemia.高α脂蛋白血症患者人巨噬细胞的血浆胆固醇外排能力增强。
Atherosclerosis. 2014 May;234(1):193-9. doi: 10.1016/j.atherosclerosis.2014.02.032. Epub 2014 Mar 12.
8
Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.烟酸与他汀类药物联合治疗动脉粥样硬化消退和预防心血管疾病事件:调和 AIM-HIGH(代谢综合征伴低 HDL/高甘油三酯患者中的动脉粥样硬化血栓形成干预:对全球健康结局的影响)试验与之前的替代终点试验。
J Am Coll Cardiol. 2012 Jun 5;59(23):2058-64. doi: 10.1016/j.jacc.2012.01.045. Epub 2012 Apr 18.
9
High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis.高密度脂蛋白亚类与非心血管、非癌症慢性炎症相关事件及心血管事件的比较:动脉粥样硬化多族裔研究
J Am Heart Assoc. 2015 Sep 14;4(9):e002295. doi: 10.1161/JAHA.115.002295.
10
Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies.波兰成年人群的全球心血管疾病死亡风险:在多中心全国性WOBASZ和WOBASZ老年研究中对队列的前瞻性评估。
Kardiol Pol. 2016;74(3):262-73. doi: 10.5603/KP.a2015.0175. Epub 2015 Sep 14.

引用本文的文献

1
Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22).北京社区2型糖尿病患者的Framingham风险评分改善:多因素干预对心血管危险因素影响的10年前瞻性研究(北京社区糖尿病研究22)
Diabetes Ther. 2020 Apr;11(4):885-903. doi: 10.1007/s13300-020-00782-5. Epub 2020 Feb 21.
2
Cardiovascular risk assessment models: Have we found the perfect solution yet?心血管风险评估模型:我们找到完美的解决方案了吗?
J Nucl Cardiol. 2020 Dec;27(6):2375-2385. doi: 10.1007/s12350-019-01642-x. Epub 2019 Feb 21.

本文引用的文献

1
HDL re-examined.高密度脂蛋白的重新审视。
Curr Opin Lipidol. 2015 Apr;26(2):127-32. doi: 10.1097/MOL.0000000000000161.
2
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting.在择期冠状动脉旁路移植术的冠心病患者中,高密度脂蛋白胆固醇没有保护作用。
Eur Heart J. 2013 Dec;34(46):3557-62. doi: 10.1093/eurheartj/eht163. Epub 2013 May 22.
3
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.烟酸在接受强化他汀类药物治疗的低 HDL 胆固醇水平患者中的应用。
N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15.
4
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.冠心病患者中 HDL 对 eNOS 激活途径产生不良影响的机制。
J Clin Invest. 2011 Jul;121(7):2693-708. doi: 10.1172/JCI42946. Epub 2011 Jun 23.
5
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.高密度脂蛋白与心血管疾病:致病和保护机制。
Nat Rev Cardiol. 2011 Apr;8(4):222-32. doi: 10.1038/nrcardio.2010.222. Epub 2011 Feb 8.
6
An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study.QRISK2 心血管疾病风险评分的独立和外部验证:一项前瞻性开放队列研究。
BMJ. 2010 May 13;340:c2442. doi: 10.1136/bmj.c2442.
7
The role of dysfunctional HDL in atherosclerosis.功能失调的高密度脂蛋白在动脉粥样硬化中的作用。
J Lipid Res. 2009 Apr;50 Suppl(Suppl):S145-9. doi: 10.1194/jlr.R800036-JLR200. Epub 2008 Oct 27.
8
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.预测英格兰和威尔士的心血管疾病风险:QRISK2的前瞻性推导与验证
BMJ. 2008 Jun 28;336(7659):1475-82. doi: 10.1136/bmj.39609.449676.25. Epub 2008 Jun 23.
9
The Yin and Yang of high-density lipoprotein cholesterol.高密度脂蛋白胆固醇的阴阳学说
J Am Coll Cardiol. 2008 Feb 12;51(6):643-4. doi: 10.1016/j.jacc.2007.10.033.
10
Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia.高α脂蛋白血症的分子机制、脂蛋白异常及致动脉粥样硬化性
Atherosclerosis. 2000 Oct;152(2):271-85. doi: 10.1016/s0021-9150(00)00574-8.